


Polar Capital Funds plc - Biotechnology Fund Class I EUR Distribution Shares / IE00B3WVRB16 / A1W70L / Polar

Last 11/07/2024 ¹	Region	Branch	Type of yield	Type
47.68 EUR	Worldwide	Sector Biotechnology	reinvestment	Equity Fund



Risk key figures

SRI	1	2	3	4	5	6	7	
Mountain-View Funds Rating ²							EDA ³	74

Yearly Performance

2023	+11.97%
2022	-1.08%
2021	+12.65%
2020	+29.19%
2019	+33.69%

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	5.00%	Minimum investment	USD 1,000,000.00
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Biotechnology	Deposit fees	0.00%	UCITS / OGAW	Yes
Fund domicile	Ireland	Redemption charge	0.00%	Performance fee	10.00%
Tranch volume	(11/07/2024) USD 1,177.86 mill.	Ongoing charges	-	Redeployment fee	0.00%
Total volume	-	Dividends		Investment company	
Launch date	10/31/2013	Polar Capital			
KESr report funds	Yes	16 Palace Street, SW1E 5JD, London			
Business year start	01.01.	United Kingdom			
Sustainability type	-	https://www.polarcapital.co.uk			
Fund manager	David Pinniger				

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	+8.24%	+11.25%	+19.08%	+40.32%	+29.53%	+28.00%	+123.64%	+200.63%
Performance p.a.	-	-	-	+40.19%	+13.79%	+8.58%	+17.44%	+14.91%
Sharpe ratio	7.42	1.12	1.02	1.85	0.59	0.26	0.61	0.54
Volatility	20.34%	18.24%	19.41%	20.19%	18.29%	21.51%	23.70%	21.96%
Worst month	-	-5.94%	-6.52%	-6.52%	-6.52%	-10.98%	-10.98%	-10.98%
Best month	-	7.24%	14.76%	14.76%	14.76%	14.76%	18.81%	18.81%
Maximum loss	-3.85%	-9.59%	-11.62%	-11.62%	-16.01%	-23.54%	-30.67%	-

Distribution permission

Austria, Germany, Switzerland, Czech Republic

¹ Important note on update status: The displayed date refers exclusively to the calculation of the NAV.

² The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

Polar Capital Funds plc - Biotechnology Fund Class I EUR Distribution Shares / IE00B3WVRB16 / A1W70L / Polar

Investment strategy


The Fund is broadly diversified across countries, biotechnology sectors and by market-cap (a measure of company size). The Fund may invest in financial derivatives (complex instruments based upon the value of underlying assets) for hedging, to reduce risk, to manage the Fund more efficiently, or to gain exposure to securities in a more efficient way. The Fund is actively managed and uses the NASDAQ Biotechnology Net Total Return Index (EUR) benchmark as a performance target and to calculate the performance fee. The currency of the Fund is US Dollar and the currency of this share class is Euro (EUR). Any income which the Fund generates may be paid out in the form of an annual dividend at the sole discretion of the Directors.

Investment goal


The objective of the Fund is to preserve capital and achieve long term capital appreciation by investing worldwide in the shares of biotechnology, diagnostics and life sciences tools companies.

Assessment Structure


Assets




Largest positions



Countries



Branches



Currencies

